Is APTA or REDX more profitable?

Redx Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Aptamer Group -178.52% -135.35% -44.96% Redx Pharma N/A -180.80% -43.95%

Do analysts rate APTA or HVO?

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 114.29%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Aptamer Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptamer Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation and earnings, APTA or HVO?

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptamer Group £1.38M 11.28 -£14.17M -£0.11 N/A hVIVO £46.77M 1.03 £17.84M -£0.87 N/A

Is APTA or HVO more profitable?

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity. Company Net Margins Return on Equity Return on Assets Aptamer Group -178.52% -135.35% -44.96% hVIVO -12.48% -14.65% 11.97%

Aptamer Group (APTA) Competitors

GBX 0.45 -0.04 (-7.79%)

As of 11:16 AM Eastern

Compare

APTA vs. REDX, HEMO, ETX, POLB, and HVO

Should you buy Aptamer Group stock or one of its competitors? MarketBeat compares Aptamer Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptamer Group include Redx Pharma (REDX), Hemogenyx Pharmaceuticals (HEMO), e-therapeutics (ETX), Poolbeg Pharma (POLB), and hVIVO (HVO). These companies are all part of the "biotechnology" industry.

How does Aptamer Group compare to Redx Pharma?

Aptamer Group (LON:APTA) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Aptamer Group has a beta of 0.899, meaning that its share price is 10% less volatile than the broader market. Comparatively, Redx Pharma has a beta of -0.53, meaning that its share price is 153% less volatile than the broader market.

Redx Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
Redx Pharma	N/A	-180.80%	-43.95%

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Redx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Aptamer Group	Neutral
Redx Pharma	Neutral

Aptamer Group has higher earnings, but lower revenue than Redx Pharma. Aptamer Group is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	11.28	-£14.17M	-£0.11	N/A
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A

3.0% of Aptamer Group shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by insiders. Comparatively, 18.4% of Redx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Redx Pharma beats Aptamer Group on 6 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than Aptamer Group. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A
Aptamer Group	£1.38M	11.28	-£14.17M	-£0.11	N/A

Hemogenyx Pharmaceuticals has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.899, meaning that its stock price is 10% less volatile than the broader market.

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.0% of Aptamer Group shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Comparatively, 7.3% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%
Aptamer Group	-178.52%	-135.35%	-44.96%

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Neutral
Aptamer Group	Neutral

Summary

Hemogenyx Pharmaceuticals and Aptamer Group tied by winning 5 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to e-therapeutics?

Aptamer Group (LON:APTA) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

e-therapeutics has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	11.28	-£14.17M	-£0.11	N/A
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A

3.0% of Aptamer Group shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 7.3% of Aptamer Group shares are held by company insiders. Comparatively, 59.4% of e-therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aptamer Group has a beta of 0.899, suggesting that its share price is 10% less volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled e-therapeutics'average media sentiment score.

Company	Overall Sentiment
Aptamer Group	Neutral
e-therapeutics	Neutral

e-therapeutics has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. e-therapeutics' return on equity of -38.75% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
e-therapeutics	N/A	-38.75%	-29.10%

Summary

e-therapeutics beats Aptamer Group on 7 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to Poolbeg Pharma?

Aptamer Group (LON:APTA) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Aptamer Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	11.28	-£14.17M	-£0.11	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A

3.0% of Aptamer Group shares are owned by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by company insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Poolbeg Pharma had 4 more articles in the media than Aptamer Group. MarketBeat recorded 4 mentions for Poolbeg Pharma and 0 mentions for Aptamer Group. Poolbeg Pharma's average media sentiment score of 0.37 beat Aptamer Group's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Aptamer Group	Neutral
Poolbeg Pharma	Neutral

Poolbeg Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Poolbeg Pharma's return on equity of -55.47% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
Poolbeg Pharma	N/A	-55.47%	-21.33%

Aptamer Group has a beta of 0.899, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.812, suggesting that its stock price is 81% more volatile than the broader market.

Summary

Poolbeg Pharma beats Aptamer Group on 7 of the 12 factors compared between the two stocks.

How does Aptamer Group compare to hVIVO?

Aptamer Group (LON:APTA) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

3.0% of Aptamer Group shares are owned by institutional investors. Comparatively, 11.8% of hVIVO shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by insiders. Comparatively, 4.9% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, hVIVO had 1 more articles in the media than Aptamer Group. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Aptamer Group. hVIVO's average media sentiment score of 1.27 beat Aptamer Group's score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company	Overall Sentiment
Aptamer Group	Neutral
hVIVO	Positive

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
hVIVO	-12.48%	-14.65%	11.97%

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	11.28	-£14.17M	-£0.11	N/A
hVIVO	£46.77M	1.03	£17.84M	-£0.87	N/A

Aptamer Group has a beta of 0.899, meaning that its share price is 10% less volatile than the broader market. Comparatively, hVIVO has a beta of 1.707, meaning that its share price is 71% more volatile than the broader market.

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 114.29%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Aptamer Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptamer Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

hVIVO beats Aptamer Group on 12 of the 16 factors compared between the two stocks.

Get Aptamer Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APTA vs. The Competition

Export

Metric	Aptamer Group	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£15.55M	£517.61M	£7.06B	£2.84B
Dividend Yield	N/A	3.90%	2.68%	6.17%
P/E Ratio	-4.09	3.47	27.15	368.18
Price / Sales	11.28	6,436.17	526.88	84,612.72
Price / Cash	N/A	13.13	29.22	27.87
Price / Book	2.11	85.93	10.75	7.49
Net Income	-£14.17M	-£96.07M	£3.58B	£5.89B
7 Day Performance	-7.41%	-1.18%	-2.10%	-0.48%
1 Month Performance	-12.28%	2.45%	3.32%	-1.00%
1 Year Performance	11.39%	60.93%	28.17%	61.74%

Aptamer Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APTA Aptamer Group	N/A	GBX 0.45 -7.8%	N/A	+20.8%	£15.55M	£1.38M	N/A	37
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
HEMO Hemogenyx Pharmaceuticals	N/A	GBX 779.03 -2.3%	N/A	+437.2%	£52.97M	N/A	N/A	14
ETX e-therapeutics	N/A	N/A	N/A	N/A	£52.59M	£295K	N/A	35	High Trading Volume
POLB Poolbeg Pharma	N/A	GBX 6.89 -0.1%	N/A	+118.8%	£48.58M	N/A	N/A	12	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:APTA) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptamer Group (APTA) Competitors

APTA vs. REDX, HEMO, ETX, POLB, and HVO

How does Aptamer Group compare to Redx Pharma?

Summary

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Summary

How does Aptamer Group compare to e-therapeutics?

Summary

How does Aptamer Group compare to Poolbeg Pharma?

Summary

How does Aptamer Group compare to hVIVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptamer Group (APTA) Competitors

APTA vs. REDX, HEMO, ETX, POLB, and HVO

How does Aptamer Group compare to Redx Pharma?

Which has more risk & volatility, APTA or REDX?

Is APTA or REDX more profitable?

Does the media favor APTA or REDX?

Which has better valuation and earnings, APTA or REDX?

Do insiders and institutionals hold more shares of APTA or REDX?

Summary

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Which has higher earnings & valuation, HEMO or APTA?

Which has more risk & volatility, HEMO or APTA?

Do insiders and institutionals have more ownership in HEMO or APTA?

Is HEMO or APTA more profitable?

Does the media favor HEMO or APTA?

Summary

How does Aptamer Group compare to e-therapeutics?

Which has stronger valuation & earnings, APTA or ETX?

Do institutionals and insiders have more ownership in APTA or ETX?

Which has more risk and volatility, APTA or ETX?

Does the media prefer APTA or ETX?

Is APTA or ETX more profitable?

Summary

How does Aptamer Group compare to Poolbeg Pharma?

Which has higher valuation & earnings, APTA or POLB?

Do insiders & institutionals believe in APTA or POLB?

Does the media favor APTA or POLB?

Is APTA or POLB more profitable?

Which has more volatility & risk, APTA or POLB?

Summary

How does Aptamer Group compare to hVIVO?

Do institutionals & insiders believe in APTA or HVO?

Does the media favor APTA or HVO?

Is APTA or HVO more profitable?

Which has better valuation and earnings, APTA or HVO?

Which has more risk & volatility, APTA or HVO?

Do analysts rate APTA or HVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools